Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: L2 and uvrC

Display: 10 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Wednesday, January 17, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=AND			
L3	L2 and uvrC	31	L3
L2	L1 and uvrA or uvrB	156	L2
L1	listeria or bacillus	.28975	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L4 and uvra adj mutation	1

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L5

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Wednesday, January 17, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=AND			
L5	L4 and uvra adj mutation	1	L5
L4	l2 and mutants	110	L4
L3	L2 and uvrC	31	L3
L2	L1 and uvrA or uvrB	156	L2
L1	listeria or bacillus	28975	L1

END OF SEARCH HISTORY

Sindbis virus-derived DNA vectors described here increase the utility of alphavirus-based vector systems in general and also provide a vector with broad potential applications for genetic immunization.

L2 ANSWER 24 OF 24 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 96082685 EMBASE
DN 1996082685
TI Layered amplification of gene expression with a DNA gene delivery system.
AU Driver D.A.; Latham E.M.; Polo J.M.; Belli B.A.; Banks T.A.; Chada S.; Brumm D.; Chang S.M.W.; Mento S.J.; Jolly D.J.; Dubensky Jr T.W.
CS Viagene Inc, 11055 Roselle Street,San Diego, CA 92121, United States
SO Annals of the New York Academy of Sciences, (1995) Vol. 772, pp. 261-264.
ISSN: 0077-8923 CODEN: ANYAA
CY United States
DT Journal; Conference Article
FS 004 Microbiology
022 Human Genetics
LA English
ED Entered STN: 2 Apr 1996
Last Updated on STN: 2 Apr 1996

=> e brockstedt dirk/au
E1 25 BROCKSTEDT D/AU
E2 24 BROCKSTEDT D G/AU
E3 21 --> BROCKSTEDT DIRK/AU
E4 32 BROCKSTEDT DIRK G/AU
E5 28 BROCKSTEDT E/AU
E6 11 BROCKSTEDT EKKEHARD/AU
E7 1 BROCKSTEDT F C/AU
E8 37 BROCKSTEDT H/AU
E9 1 BROCKSTEDT H C/AU
E10 2 BROCKSTEDT H J/AU
E11 51 BROCKSTEDT M/AU
E12 30 BROCKSTEDT RASMUSSEN H/AU

=> s e1-e4 and (nucleic or bacter?)
L3 43 ("BROCKSTEDT D"/AU OR "BROCKSTEDT D G"/AU OR "BROCKSTEDT DIRK"/AU OR "BROCKSTEDT DIRK G"/AU) AND (NUCLEIC OR BACTER?)

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 22 DUP REM L3 (21 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 22 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
AN 2006:239172 BIOSIS
DN PREV200600237018
TI Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.
AU Yoshimura, Kiyoshi; Jain, Ajay; Allen, Heather E.; Laird, Lindsay S.; Chia, Christina Y.; Ravi, Sowmya; Brockstedt, Dirk G.; Giedlin, Martin A.; Bahjat, Keith S.; Leong, Meredith L.; Slansky, Jill E.; Cook, David N.; Dubensky, Thomas W.; Pardoll, Drew M.; Schulick, Richard D. [Reprint Author]
CS Johns Hopkins Med Inst, Dept Surg and Oncol, Bunting Blaustein Canc Res Bldg,Suite 442,1650 Or, Baltimore, MD 21231 USA
rschulick@jhmi.edu

```
=> e dubensky jr thomas/au
E1            5      DUBENSKY HAROLD J/AU
E2            8      DUBENSKY JR T W/AU
E3            0 --> DUBENSKY JR THOMAS/AU
E4           16      DUBENSKY JR THOMAS W/AU
E5            1      DUBENSKY M/AU
E6            2      DUBENSKY M M/AU
E7            2      DUBENSKY M S/AU
E8            3      DUBENSKY M W/AU
E9            5      DUBENSKY R/AU
E10           5      DUBENSKY R A/AU
E11           7      DUBENSKY R G/AU
E12           1      DUBENSKY RICHIE/AU

=> s e2-e4
L1           24 ("DUBENSKY JR T W"/AU OR "DUBENSKY JR THOMAS"/AU OR "DUBENSKY
                JR THOMAS W"/AU)

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2           24 DUP REM L1 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 24 ANSWERS - CONTINUE? Y/(N):y

L2   ANSWER 1 OF 24  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
AN   2005375886  EMBASE
TI   Killed but metabolically active microbes: A new vaccine paradigm for
     eliciting effector T-cell responses and protective immunity.
AU   Brockstedt D.G.; Bahjat K.S.; Giedlin M.A.; Liu W.; Leong M.; Luckett W.;
     Gao Y.; Schnupf P.; Kapadia D.; Castro G.; Lim J.Y.H.; Sampson-Johannes
     A.; Herskovits A.A.; Stassinopoulos A.; Bouwer H.G.A.; Hearst J.E.;
     Portnoy D.A.; Cook D.N.; Dubensky Jr. T.W.
CS   T.W. Dubensky Jr., Cerus Corporation, 2411 Stanwell Drive, Concord, CA
     94520, United States. tom_dubensky@cerus.com
SO   Nature Medicine, (2005) Vol. 11, No. 8, pp. 853-860. .
     Refs: 46
     ISSN: 1078-8956  CODEN: NAMEFI
CY   United Kingdom
DT   Journal; Article
FS   004     Microbiology
     026     Immunology, Serology and Transplantation
     037     Drug Literature Index
LA   English
SL   English
ED   Entered STN: 22 Sep 2005
     Last Updated on STN: 22 Sep 2005
AB   We developed a new class of vaccines, based on killed but metabolically
     active (KBMA) bacteria, that simultaneously takes advantage of the potency
     of live vaccines and the safety of killed vaccines. We removed genes
     required for nucleotide excision repair (uvrAB), rendering microbial-based
     vaccines exquisitely sensitive to photochemical inactivation with psoralen
     and long-wavelength ultraviolet light. Colony formation of the nucleotide
     excision repair mutants was blocked by infrequent, randomly distributed
     psoralen crosslinks, but the bacterial population was able to express its
     genes, synthesize and secrete proteins. Using the intracellular pathogen
     Listeria monocytogenes as a model platform, recombinant
     psoralen-inactivated Lm ΔuvrAB vaccines induced potent CD4(+) and
     CD8(+) T-cell responses and protected mice against virus challenge in an
     infectious disease model and provided therapeutic benefit in a mouse
     cancer model. Microbial KBMA vaccines used either as a recombinant
     vaccine platform or as a modified form of the pathogen itself may have
     broad use for the treatment of infectious disease and cancer.
```

```
FAN.CNT 2
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     --------------        ----   --------    --------------------     --------
PI   WO 9904632             A1    19990204    WO 1998-US15461          19980724
         W:  CA, JP
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     CA 2300335             AA    19990204    CA 1998-2300335          19980724
     EP 1022948             A1    20000802    EP 1998-937129           19980724
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
PRAI US 1997-53773P         P     19970725
     US 1998-121162         A     19980723
     WO 1998-US15461        W     19980724
AB   The present invention relates generally to immunization methods using
     recombinant viral vectors.  In particular, the invention relates to
     methods and compns. for immunizing a subject with a nucleic acid
     mol. encoding an antigen of interest, wherein the nucleic acid
     mol. is delivered to the subject via a recombinant AAV virion.
     Recombinant AAV virion encoding ovalbumin gene under control of the
     cytomegalovirus promoter were constructed and used for transfecting murine
     melanoma cell line B16 to induce antitumor immunity.  Also, ability of the
     rAAV-ovalbumin to deliver transgene product into the MHC class I pathway
     was demonstrated.
RE.CNT  4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> e bahjat keith/au
E1           14      BAHJAT K/AU
E2           38      BAHJAT K S/AU
E3            8 --> BAHJAT KEITH/AU
E4           30      BAHJAT KEITH S/AU
E5            2      BAHJAT KHALID S/AU
E6            4      BAHJAT R/AU
E7            3      BAHJAT RENA/AU
E8            2      BAHJAT ZUHAIR/AU
E9           13      BAHJAT ZUHAIR S/AU
E10           2      BAHJERNEJAD M/AU
E11           1      BAHJET/AU
E12           3      BAHJI E/AU

=> s e1-e4 and (nucleic or bacter?)
L5           30 ("BAHJAT K"/AU OR "BAHJAT K S"/AU OR "BAHJAT KEITH"/AU OR "BAHJA
               T KEITH S"/AU) AND (NUCLEIC OR BACTER?)

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6           12 DUP REM L5 (18 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):y


L6   ANSWER 1 OF 12  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2006:239172  BIOSIS
DN   PREV200600237018
TI   Selective targeting of antitumor immune responses with engineered
     live-attenuated Listeria monocytogenes.
AU   Yoshimura, Kiyoshi; Jain, Ajay; Allen, Heather E.; Laird, Lindsay S.;
     Chia, Christina Y.; Ravi, Sowmya; Brockstedt, Dirk G.; Giedlin, Martin A.;
     Bahjat, Keith S.; Leong, Meredith L.; Slansky, Jill E.; Cook,
     David N.; Dubensky, Thomas W.; Pardoll, Drew M.; Schulick, Richard D.
```

```
E2          27     HEARST J R/AU
E3          10 --> HEARST JOHN/AU
E4         335     HEARST JOHN E/AU
E5           7     HEARST JOHN EUGENE/AU
E6           1     HEARST JONENA/AU
E7           3     HEARST JOSEPH R/AU
E8           7     HEARST L/AU
E9           3     HEARST L E/AU
E10         16     HEARST M/AU
E11         20     HEARST M A/AU
E12          2     HEARST M I/AU

=> s e3-e4 and (nucleic or bacter?)
L7         117 ("HEARST JOHN"/AU OR "HEARST JOHN E"/AU) AND (NUCLEIC OR BACTER?
               )

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8         106 DUP REM L7 (11 DUPLICATES REMOVED)

=> s l8 and attenuat?
L9           3 L8 AND ATTENUAT?

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L9   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:100445  CAPLUS
DN   142:196505
TI   Modified free-living microbes for loading and inducing antigen-presenting
     cells and uses as vaccines and methods of therapeutic use thereof
IN   Dubensky, Thomas W., Jr.; Brockstedt, Dirk G.; Bahjat, Keith; Hearst,
     John E.; Cook, David; Luckett, William Stanford
PA   Cerus Corporation, USA
SO   PCT Int. Appl., 291 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 6
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    -------------------      --------
PI   WO 2005009463        A2     20050203    WO 2004-US23881          20040723
     WO 2005009463        A3     20050602
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     US 2004197343        A1     20041007    US 2004-773618           20040206
     US 2004228877        A1     20041118    US 2004-773792           20040206
     WO 2005071088        A2     20050804    WO 2004-US44080          20041223
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
```

```
CLMN    Number of Claims: 82
ECL     Exemplary Claim: 1
DRWN    51 Drawing Page(s)
LN.CNT 7204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Free-living microbes are provided in which the nucleic acid
        has been modified so that the microbe is attenuated for
        proliferation and/or which comprise genetic mutations that
        attenuate the ability of the microbe to repair its
        nucleic acid. Methods of using the modified microbes for the
        loading, activation, and/or maturation of antigen-presenting cells are
        also provided. Vaccine compositions comprising the modified microbes
        and/or the antigen-presenting cells and methods of using the vaccines
        are also provided. The microbes may be further modified to include
        heterologous antigens, such as tumor antigens or infectious disease
        antigens, for use as a vaccine against cancer or infectious diseases.


=> e cook david/au
E1            5      COOK DARZENS S/AU
E2            5      COOK DAVE/AU
E3          187 --> COOK DAVID/AU
E4          126      COOK DAVID A/AU
E5            2      COOK DAVID ALAN/AU
E6            4      COOK DAVID ALASTAIR/AU
E7            3      COOK DAVID ALLAN/AU
E8            4      COOK DAVID ANTHONY/AU
E9           53      COOK DAVID B/AU
E10          10      COOK DAVID BRANSTON/AU
E11           1      COOK DAVID BRAUSTON/AU
E12           1      COOK DAVID BURFORD/AU

=> e cook david n/au
E1           67      COOK DAVID M/AU
E2            1      COOK DAVID MICHAEL/AU
E3           37 --> COOK DAVID N/AU
E4            1      COOK DAVID NELSON/AU
E5            3      COOK DAVID O/AU
E6            8      COOK DAVID P/AU
E7            2      COOK DAVID PHILIP/AU
E8           39      COOK DAVID R/AU
E9            6      COOK DAVID S/AU
E10           1      COOK DAVID STANLEY/AU
E11           1      COOK DAVID T/AU
E12          28      COOK DAVID W/AU

=> s e3-e4 and (nucleic or bacter?)
L10          26 ("COOK DAVID N"/AU OR "COOK DAVID NELSON"/AU) AND (NUCLEIC OR
                BACTER?)

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11          18 DUP REM L10 (8 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 18 ANSWERS - CONTINUE? Y/(N):y


L11  ANSWER 1 OF 18  BIOSIS  COPYRIGHT (c) 2006 The Thomson Corporation  on STN
AN   2006:239172  BIOSIS
DN   PREV200600237018
TI   Selective targeting of antitumor immune responses with engineered
     live-attenuated Listeria monocytogenes.
AU   Yoshimura, Kiyoshi; Jain, Ajay; Allen, Heather E.; Laird, Lindsay S.;
```